Dr. Axel Mescheder (CEO and CMO)
Dr. Mescheder joined Cristal Therapeutics in November 2018 as Chief Executive Officer and Chief Medical Officer.
Dr. Mescheder brings over 25 years of clinical development and regulatory experience from his senior management roles in the pharmaceutical and biotechnology industry. He has a track record of developing, implementing and driving clinical development programs that have led to successful product registrations or label extensions, in both Europe and the U.S. Dr. Mescheder’s expertise spans across a number of therapeutic areas including oncology, immunology and inflammation.
Previously he worked as Chief Medical and Development Officer at a number of major biopharmaceutical companies, including Lanthio Pharma (a MorphoSys AG company), TopoTarget and MediGene.
He also served in senior management roles at Medpace, MorphoSys, the Genetics Institute (Wyeth-Ayerst Research, a division of Pfizer), and Centeon Pharma (CSL Behring) and Hoffman-La Roche.
Dr. Mescheder is a board certified Medical Specialist in Pharmacology and Toxicology and holds a Dr. med. Degree from Chr.-Albrechts-University, Kiel, Germany.